Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia

NCT00313053 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Lymphocytic, Acute
Leukemia
Acute Lymphoid Leukemia (ALL)

Interventions

DRUG: Human mAb 216
DRUG: Vincristine

Sponsor

Clare Twist

Collaborators

[object Object]